CN106661113A - Hiv抗体治疗作为治疗替代 - Google Patents
Hiv抗体治疗作为治疗替代 Download PDFInfo
- Publication number
- CN106661113A CN106661113A CN201580044550.6A CN201580044550A CN106661113A CN 106661113 A CN106661113 A CN 106661113A CN 201580044550 A CN201580044550 A CN 201580044550A CN 106661113 A CN106661113 A CN 106661113A
- Authority
- CN
- China
- Prior art keywords
- hiv
- pro
- experimenter
- treatment
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039620P | 2014-08-20 | 2014-08-20 | |
| US62/039,620 | 2014-08-20 | ||
| US201562192941P | 2015-07-15 | 2015-07-15 | |
| US62/192,941 | 2015-07-15 | ||
| PCT/US2015/046160 WO2016029049A1 (en) | 2014-08-20 | 2015-08-20 | Hiv antibody therapy as treatment substitute |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106661113A true CN106661113A (zh) | 2017-05-10 |
Family
ID=55351264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580044550.6A Pending CN106661113A (zh) | 2014-08-20 | 2015-08-20 | Hiv抗体治疗作为治疗替代 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10562969B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3183270B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6767367B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170042706A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106661113A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015305401A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017003252A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2957817A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2880950T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017002093A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016029049A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024008177A1 (en) * | 2022-07-08 | 2024-01-11 | Nanjing Curegene Technology Co., Ltd. | Engineered cells and uses thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016210130A1 (en) | 2015-06-23 | 2016-12-29 | Cytodyn Inc. | Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| CN111886249A (zh) * | 2017-09-18 | 2020-11-03 | 西托戴恩股份有限公司 | 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008134076A1 (en) * | 2007-04-30 | 2008-11-06 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| CN101495145A (zh) * | 2005-07-22 | 2009-07-29 | 原基因药物有限公司 | 用于减少受hiv-1感染的患者中病毒负荷的方法 |
| US20130216526A1 (en) * | 2008-04-30 | 2013-08-22 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1 infected patients |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| RU2353357C2 (ru) | 2003-05-16 | 2009-04-27 | Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют | Композиции для супрессии экспрессии ccr5 и способы их применения |
| SG184355A1 (en) * | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
-
2015
- 2015-08-20 BR BR112017003252A patent/BR112017003252A2/pt not_active Application Discontinuation
- 2015-08-20 MX MX2017002093A patent/MX2017002093A/es unknown
- 2015-08-20 JP JP2017529600A patent/JP6767367B2/ja not_active Expired - Fee Related
- 2015-08-20 ES ES15832985T patent/ES2880950T3/es active Active
- 2015-08-20 KR KR1020177007086A patent/KR20170042706A/ko not_active Ceased
- 2015-08-20 CN CN201580044550.6A patent/CN106661113A/zh active Pending
- 2015-08-20 CA CA2957817A patent/CA2957817A1/en not_active Abandoned
- 2015-08-20 AU AU2015305401A patent/AU2015305401A1/en not_active Abandoned
- 2015-08-20 WO PCT/US2015/046160 patent/WO2016029049A1/en not_active Ceased
- 2015-08-20 EP EP15832985.4A patent/EP3183270B1/en active Active
- 2015-08-20 US US15/504,928 patent/US10562969B2/en not_active Expired - Fee Related
- 2015-08-20 EP EP21166771.2A patent/EP3904390A1/en not_active Withdrawn
-
2020
- 2020-01-08 US US16/737,291 patent/US20200385475A1/en not_active Abandoned
- 2020-09-17 JP JP2020155978A patent/JP7035143B2/ja not_active Expired - Fee Related
-
2021
- 2021-04-07 AU AU2021202132A patent/AU2021202132A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101495145A (zh) * | 2005-07-22 | 2009-07-29 | 原基因药物有限公司 | 用于减少受hiv-1感染的患者中病毒负荷的方法 |
| WO2008134076A1 (en) * | 2007-04-30 | 2008-11-06 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| US20130216526A1 (en) * | 2008-04-30 | 2013-08-22 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1 infected patients |
Non-Patent Citations (3)
| Title |
|---|
| JEFFREY M. JACOBSON ET AL.: "Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody", 《J INFECT DIS.》 * |
| JEFFREY M. JACOBSON ET AL.: "Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
| KUSH DHODY ET AL.: "PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection", 《HIV CLINICAL TRIALS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024008177A1 (en) * | 2022-07-08 | 2024-01-11 | Nanjing Curegene Technology Co., Ltd. | Engineered cells and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3183270B1 (en) | 2021-04-28 |
| JP7035143B2 (ja) | 2022-03-14 |
| MX2017002093A (es) | 2017-05-25 |
| EP3183270A4 (en) | 2018-01-17 |
| ES2880950T3 (es) | 2021-11-26 |
| EP3183270A1 (en) | 2017-06-28 |
| AU2015305401A1 (en) | 2017-03-02 |
| JP6767367B2 (ja) | 2020-10-14 |
| AU2021202132A1 (en) | 2021-05-06 |
| US20200385475A1 (en) | 2020-12-10 |
| BR112017003252A2 (pt) | 2017-11-28 |
| WO2016029049A1 (en) | 2016-02-25 |
| US10562969B2 (en) | 2020-02-18 |
| EP3904390A1 (en) | 2021-11-03 |
| JP2021004249A (ja) | 2021-01-14 |
| KR20170042706A (ko) | 2017-04-19 |
| US20170335002A1 (en) | 2017-11-23 |
| JP2017527613A (ja) | 2017-09-21 |
| CA2957817A1 (en) | 2016-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sacco et al. | European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention | |
| McArthur et al. | Human immunodeficiency virus‐associated neurocognitive disorders: Mind the gap | |
| Fulcher et al. | Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection | |
| Katlama et al. | TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results | |
| Rafatpanah et al. | The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran | |
| Bellio et al. | Proof-of-concept trial of an amniotic fluid-derived extracellular vesicle biologic for treating high risk patients with mild-to-moderate acute COVID-19 infection | |
| M Amedee et al. | Chronic alcohol abuse and HIV disease progression: studies with the non-human primate model | |
| Choi | Convalescent plasma therapy for coronavirus disease 2019 | |
| JP7035143B2 (ja) | 代替処置としてのhiv抗体療法 | |
| Zhang et al. | Efficacy and safety of tripterygium wilfordii Hook F plus TNF inhibitor for active rheumatoid arthritis: A multicentre, randomized, double-blind, triple-dummy controlled trial | |
| Li et al. | Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection | |
| Touzard Romo et al. | Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175) | |
| Ma et al. | Therapeutic antibodies under development for SARS‐CoV‐2 | |
| Liang et al. | Efficacy and safety of Opinercept tumor necrosis factor inhibitor therapy for Drug-Refractory rheumatoid arthritis: a randomized clinical trial | |
| Hadia et al. | A Comprehensive Review of the Safety and Efficacy of Lenacapavir in the Treatment of Human Immunodeficiency Virus. | |
| HK40063361A (en) | Hiv antibody therapy as treatment substitute | |
| Zhao et al. | Monoclonal CCR5 antibody: a promising therapy for HIV | |
| Antar et al. | CROI 2025: Acute and Postacute COVID-19 | |
| Plummer et al. | COVID-19 Vaccines for HIV-Infected Patients. Viruses 2021, 13, 1890 | |
| Demır et al. | A 12-month, open label, multicenter pilot study evaluating fingolimod treatment in terms of patient satisfaction in relapsing remitting multiple sclerosis patients-FINE trial | |
| AbdelMassih et al. | Non-Multisystem Inflammatory Syndrome in Children—Postacute Sequelae of Paediatric COVID-19: Autoimmune or Autoinflammatory? A Systematic Review of the Reported Cases. Rheumato 2023, 3, 132–168 | |
| Declerck et al. | Clinical characteristics and treatments of imported loiasis patients with microfilaraemia diagnosed in France, 2000-2022 | |
| Peterson | The Efficacy of Tocilizumab as a Therapeutic Treatment for SARS-CoV-2 Infections: An Integrative Literature Review | |
| Hakroush et al. | Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis | |
| Hespen | Guillain-Barre Syndrome: A Review of Current Diagnostic Tools, Treatments, and Research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |